Urogen Pharma (NASDAQ:URGN) General Counsel Jason Drew Smith Sells 1,519 Shares

Urogen Pharma (NASDAQ:URGN) General Counsel Jason Smith sold 1,519 shares of the firm’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $42.54, for a total transaction of $64,618.26. Following the sale, the general counsel owned 53,141 shares in the company, valued at approximately $2,260,618.14. This trade represents a 2.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Urogen Pharma Stock Up 2.7%

Shares of Urogen Pharma stock opened at $45.00 on Thursday. Urogen Pharma has a fifty-two week low of $15.86 and a fifty-two week high of $50.81. The business’s fifty day moving average is $43.16 and its two-hundred day moving average is $31.31. The firm has a market cap of $2.20 billion, a PE ratio of -22.73 and a beta of 1.57.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The firm had revenue of $72.46 million during the quarter, compared to analyst estimates of $63.55 million. Equities research analysts anticipate that Urogen Pharma will post -0.2 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Paradigm Biocapital Advisors LP purchased a new stake in Urogen Pharma during the 3rd quarter worth $84,111,000. BlackRock Inc. purchased a new position in Urogen Pharma in the second quarter valued at about $117,814,000. Jefferies Financial Group Inc. purchased a new position in Urogen Pharma in the second quarter valued at about $80,947,000. Soleus Capital Management L.P. acquired a new position in shares of Urogen Pharma during the second quarter worth about $29,934,000. Finally, California State Teachers Retirement System lifted its stake in shares of Urogen Pharma by 4,168.7% during the second quarter. California State Teachers Retirement System now owns 1,654,123 shares of the company’s stock worth $60,872,000 after purchasing an additional 1,615,373 shares in the last quarter. Hedge funds and other institutional investors own 91.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on URGN shares. TD Cowen upped their price objective on shares of Urogen Pharma from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. UBS Group reissued a “buy” rating on shares of Urogen Pharma in a research report on Thursday, July 9th. Guggenheim boosted their target price on shares of Urogen Pharma from $42.00 to $58.00 and gave the company a “buy” rating in a report on Thursday, August 6th. HC Wainwright upped their price target on shares of Urogen Pharma from $45.00 to $75.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Finally, Oppenheimer increased their price target on shares of Urogen Pharma from $40.00 to $50.00 and gave the stock an “outperform” rating in a research note on Thursday, July 16th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Urogen Pharma presently has an average rating of “Moderate Buy” and an average price target of $52.38.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.